Previous 10 | Next 10 |
Following the successful conclusion of three clinical trials, approximately 120 patients continue treatment with leronlimab in extension arms VANCOUVER, Washington, May 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company")...
RADNOR, PA / ACCESSWIRE / April 30, 2021 / The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn") that a securities fraud class action lawsuit has been filed against CytoDyn on behalf of those who purchased or acquired CytoDyn common...
VANCOUVER, Washington, April 27, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indic...
Inovio failed at a pandemic vaccine again. This is the seventh time and that constitutes a large red flag. Yet, I'm changing my opinion. For further details see: Inovio Keeps Its Perfect Track Record
Company Achieves Total Financing in April of $57 Million VANCOUVER, Washington, April 22, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140), ...
Under a rolling review, CytoDyn (CYDY) has submitted the manufacturing section ((CMC)) of the application for an Interim Order to Health Canada for leronlimab to be considered as a therapeutic for COVID-19.The application documents the Company’s manufacturing practices are in full comp...
Clinical trial in U.S. for critically ill COVID-19 patients expected to initiate soon CytoDyn in discussions with Brazil to initiate two COVID-19 trials, one for severe and one for critically ill patients VANCOUVER, Washington, April 19, 2021 (GLOBE NEWSWIRE) -- CytoDyn ...
CytoDyn is following all patients treated with leronlimab under CSP and will provide additional information when available and authorized for release VANCOUVER, Washington, April 19, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “...
Somewhat ineffective vaccine policy in need of assistance. Vaccines may lose ground to COVID variants. Todos Medical's diagnostic-therapy combo could be the best solution. Supplements and oral antivirals slow the virus. For further details see: The Rise Of Oral COVID...
CytoDyn ([[CYDY]]) announces that it has executed an exclusive supply and distribution agreement with Chiral Pharma to supply up to 200K vials of leronlimab to critically ill COVID-19 patients in the Philippines under Compassionate Special Permit ((CSP))authorizations."......
News, Short Squeeze, Breakout and More Instantly...
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a bio...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...